JP7159302B2 - 線維性疾患の治療のための方法 - Google Patents

線維性疾患の治療のための方法 Download PDF

Info

Publication number
JP7159302B2
JP7159302B2 JP2020516787A JP2020516787A JP7159302B2 JP 7159302 B2 JP7159302 B2 JP 7159302B2 JP 2020516787 A JP2020516787 A JP 2020516787A JP 2020516787 A JP2020516787 A JP 2020516787A JP 7159302 B2 JP7159302 B2 JP 7159302B2
Authority
JP
Japan
Prior art keywords
group
pharmaceutical composition
cells
pulmonary fibrosis
bleomycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020516787A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522567A5 (enExample
JP2020522567A (ja
Inventor
ハン，ルオラン
ノースラップ，ジョン
カシバトラ，スリニバス・ラオ
ホリガン，スティーブン
ラーソン，ジェフ
Original Assignee
イテリオン・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イテリオン・セラピューティクス・インコーポレイテッド filed Critical イテリオン・セラピューティクス・インコーポレイテッド
Publication of JP2020522567A publication Critical patent/JP2020522567A/ja
Publication of JP2020522567A5 publication Critical patent/JP2020522567A5/ja
Application granted granted Critical
Publication of JP7159302B2 publication Critical patent/JP7159302B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020516787A 2017-06-02 2018-06-01 線維性疾患の治療のための方法 Active JP7159302B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762514541P 2017-06-02 2017-06-02
US62/514,541 2017-06-02
PCT/US2018/035646 WO2018223023A1 (en) 2017-06-02 2018-06-01 Methods for treatment of fibrotic diseases

Publications (3)

Publication Number Publication Date
JP2020522567A JP2020522567A (ja) 2020-07-30
JP2020522567A5 JP2020522567A5 (enExample) 2021-07-26
JP7159302B2 true JP7159302B2 (ja) 2022-10-24

Family

ID=64456126

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020516787A Active JP7159302B2 (ja) 2017-06-02 2018-06-01 線維性疾患の治療のための方法

Country Status (5)

Country Link
US (2) US11298346B2 (enExample)
EP (2) EP4656191A1 (enExample)
JP (1) JP7159302B2 (enExample)
CA (1) CA3065318A1 (enExample)
WO (1) WO2018223023A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4656191A1 (en) * 2017-06-02 2025-12-03 Iterion Therapeutics, Inc. Methods for treatment of fibrotic diseases
WO2019099836A1 (en) * 2017-11-16 2019-05-23 Northwestern University Inhaled formulation of a molecular inhibitor of wnt/beta-catenin signaling for treating interstitial lung diseases
CA3101994A1 (en) * 2018-06-01 2019-12-05 Iterion Therapeutics, Inc. Formulations of tegavivint and related compounds
EP4081209A4 (en) * 2019-12-24 2024-04-24 The Regents of the University of California Compositions and methods for treating cancer and improving epithelial homeostasis
CA3176457A1 (en) * 2020-04-08 2021-10-14 The Trustees Of Indiana University Therapeutic strategies to manage facial contractures post injury
US11136307B1 (en) * 2020-09-29 2021-10-05 Iterion Therapeutics, Inc. Crystalline form of tegavivint, method of preparation, and use thereof
US11964054B2 (en) 2020-11-24 2024-04-23 Iterion Therapeutics, Inc. Formulations of tegavivint
US11571388B2 (en) 2020-11-24 2023-02-07 Iterion Therapeutics, Inc. Lyophilized formulations of tegavivint
CN119215047A (zh) * 2024-10-11 2024-12-31 浙江大学 一种芳香磺酰胺类化合物在制备防治肝损伤药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013513625A (ja) 2009-12-15 2013-04-22 ザ・ホスピタル・フォー・シック・チルドレン ネホパム化合物を使用して、瘢痕およびβ−カテニン媒介障害を治療する方法
JP2014534229A (ja) 2011-11-06 2014-12-18 ベータ キャット ファーマシューティカルズ リミテッド ライアビリティ カンパニー 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法
JP2016512547A (ja) 2013-03-14 2016-04-28 キュアジェニックス インコーポレイテッド 線維症疾患の治療のための化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871493C (en) * 2007-05-10 2017-03-28 Dogwood Pharmaceuticals, Inc. Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
EA030302B1 (ru) 2008-11-21 2018-07-31 Форест Лэборетериз Холдингз Лимитед Антрахинондиоксимы и их применение
US20130123281A1 (en) * 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules
US9725473B2 (en) 2015-07-28 2017-08-08 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compound prodrugs and their uses
KR102651136B1 (ko) * 2016-04-12 2024-03-25 삼성디스플레이 주식회사 유기 발광 표시 장치 및 그 제조 방법
EP4656191A1 (en) * 2017-06-02 2025-12-03 Iterion Therapeutics, Inc. Methods for treatment of fibrotic diseases
CA3101994A1 (en) * 2018-06-01 2019-12-05 Iterion Therapeutics, Inc. Formulations of tegavivint and related compounds
US11571388B2 (en) * 2020-11-24 2023-02-07 Iterion Therapeutics, Inc. Lyophilized formulations of tegavivint

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013513625A (ja) 2009-12-15 2013-04-22 ザ・ホスピタル・フォー・シック・チルドレン ネホパム化合物を使用して、瘢痕およびβ−カテニン媒介障害を治療する方法
JP2014534229A (ja) 2011-11-06 2014-12-18 ベータ キャット ファーマシューティカルズ リミテッド ライアビリティ カンパニー 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法
JP2016512547A (ja) 2013-03-14 2016-04-28 キュアジェニックス インコーポレイテッド 線維症疾患の治療のための化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Cell Communication and Signaling，2016年，10，33-40
Physiological Research，2012年，61，337-346

Also Published As

Publication number Publication date
EP3630101B1 (en) 2025-10-08
WO2018223023A1 (en) 2018-12-06
US20230012615A1 (en) 2023-01-19
JP2020522567A (ja) 2020-07-30
US11298346B2 (en) 2022-04-12
EP4656191A1 (en) 2025-12-03
EP3630101A4 (en) 2021-01-20
US20180344713A1 (en) 2018-12-06
CA3065318A1 (en) 2018-12-06
EP3630101A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
JP7159302B2 (ja) 線維性疾患の治療のための方法
AU2003249476B2 (en) Synergistic combination of an alpha-2-delta ligand and a PDEV inhibitor for use in the treatment of pain
KR101855358B1 (ko) 골암통증에서의 시그마 리간드의 용도
US20040157847A1 (en) Synergistic combinations
AU2014301220A1 (en) Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
JP5425229B2 (ja) Ｎｋ受容体アンタゴニストの使用
KR100750782B1 (ko) 칼슘 채널 알파-2-델타 서브유닛에 대한 친화성을 갖는 프롤린 유도체
JP6539206B2 (ja) 肺高血圧症の治療のためのベータ−３アドレナリン受容体アゴニストの使用
WO2018237174A2 (en) Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease
JP2016029033A (ja) 組合せ物
WO2020067333A1 (ja) 線維症治療用医薬組成物
EP1648450A1 (de) Arzneimittel enthaltend derivate von aryl(oder heteroaryl)azolylcarbinolen
JP6907174B2 (ja) アミロイド線維形成の抑制又は阻害剤
TW200536846A (en) Combination of voriconazole and an antifungal CYP2C19 inhibitor
EP2676954A1 (en) Heterocyclyl-substituted-phenyl derivatives as vasodilators
US20080293746A1 (en) Combinations comprising pregabalin
JP2022065212A (ja) 組織線維化による疾患の予防又は治療のための医薬
NZ765534A (en) P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220913

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221012

R150 Certificate of patent or registration of utility model

Ref document number: 7159302

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250